RVMD
RVMD clinical trials: Revolution Medicines, Inc.
Every trial on ClinicalTrials.gov where Revolution Medicines, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 26
- Trials linked
- 20
- As lead sponsor
- 6
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
RVMD on the catalyst calendar · RVMD registry changes
- Primary completion Apr 2028Sponsor estimatePhase 3NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRevolution Medicines, Inc. · Pancreatic CancerRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 3NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic...Revolution Medicines, Inc. · Pancreatic CancerRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2028Sponsor estimatePhase 3NCT07621718Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic...Revolution Medicines, Inc. · Pancreatic CancerRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2027Sponsor estimatePhase 3NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Revolution Medicines, Inc. · NSCLC (Non-small Cell Lung Cancer)RecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimatePhase 3NCT07777822Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic...Revolution Medicines, Inc. · NSCLCRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2029Sponsor estimatePhase 1/Phase 2NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRevolution Medicines, Inc. · Advanced Solid TumorsRecruitingRVMDLeadSMMTCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 10, 2029Sponsor estimatePhase 3NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Revolution Medicines, Inc. · Pancreatic CancerRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRevolution Medicines, Inc. · Non-Small Cell Lung Cancer, NSCLCRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 1/Phase 2NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRevolution Medicines, Inc. · Non-Small Cell Lung Cancer (NSCLC)RecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2028Sponsor estimatePhase 1/Phase 2NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRevolution Medicines, Inc. · Colorectal CancerRecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 1NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRevolution Medicines, Inc. · Non-small Cell Lung Cancer (NSCLC)RecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07573215Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaRevolution Medicines, Inc. · PDACApproved for marketingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRevolution Medicines, Inc. · Non-small Cell Lung Cancer (NSCLC)RecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 3NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Revolution Medicines, Inc. · Pancreatic CancerActive, not recruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2027Sponsor estimatePhase 1NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc. · Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimatePhase 1/Phase 2NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRevolution Medicines, Inc. · Non-small Cell Lung Cancer (NSCLC)RecruitingRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2024ActualPhase 2NCT05054725Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesRevolution Medicines, Inc. · Non-Small Cell Lung Cancer
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2024ActualPhase 1NCT04774952Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc. · Solid TumorsCompletedRVMDLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 8, 2022ActualPhase 1/Phase 2NCT03989115Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc. · Solid TumorCompletedRVMDLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2023Sponsor estimatePhase 1NCT03634982Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc. · Solid TumorsUnknown statusRVMDLeadSNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2030Sponsor estimatePhase 2NCT07793253Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Biliary Tract CancersNot yet recruitingRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2029Sponsor estimatePhase 1NCT07756281First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerParVation Therapeutics, Inc. · Pancreatic CancerRecruitingRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1/Phase 2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc. · PDACRecruitingTNGXLeadRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2029Sponsor estimatePhase 1NCT07898813Daraxonrasib in Resectable PDACDana-Farber Cancer Institute · Pancreatic Ductal AdenocarcinomaNot yet recruitingRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2025ActualPhase 1NCT05557292RMC-5552 Monotherapy in Adult Subjects With Recurrent GlioblastomaNicholas Butowski · GlioblastomaTerminatedRVMDCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 1 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner